Sangamo Q2 net loss $114.5M, revenue down 77% YoY; impairments of $51.3M

SANGAMO THERAPEUTICS, INC

2023-Q2 EPS reported -$0.54 revenue$164,792,000

Net loss $114.5M ($0.66/sh) vs $43.2M ($0.29/sh) YoY, driven by $51.3M intangible asset impairment.
Revenue $6.8M vs $29.4M YoY, down 77% due to terminations of Novartis, Biogen, Sanofi deals.
Total GAAP op expenses $130.4M (incl. $51.3M impairment); non-GAAP op expenses $72.3M.
Cash & marketable securities $182.1M at June 30; raised $15.1M via ATM; cash runway >12 months.
Updated 2023 GAAP op expense guidance $378-398M; non-GAAP unchanged at $240-260M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.